Question

A 58-year-old with symptomatic HFrEF (LVEF 30%) on an ACE inhibitor, evidence-based beta-blocker, and spironolactone remains NYHA II. Which additional therapy improves morbidity and mortality regardless of diabetes status?

Accepted Answer

Add an SGLT2 inhibitor

Answer

Ivabradine

Answer

Digoxin

Answer

Hydralazine alone

Answer

Isosorbide mononitrate alone

Practice question

A 58-year-old with symptomatic HFrEF (LVEF 30%) on an ACE inhibitor, evidence-based beta-blocker, and spironolactone remains NYHA II. Which additional therapy improves morbidity and mortality regardless of diabetes status?